secwatch / observer
8-K filed December 12, 2022, 6:59 PM ET ticker ASMB CIK 0001426800
leadership confidence high sentiment neutral materiality 0.50

Assembly Bio finalizes CEO succession; Okazaki takes role Jan 1, 2023; board cuts quorum

ASSEMBLY BIOSCIENCES, INC.

item 5.02item 5.03item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jason A. Okazaki

Chief Executive Officer
ASMB · ASSEMBLY BIOSCIENCES, INC.
Effective
2023-01-01
Filed
December 12, 2022, 6:59 PM ET
Jason A. Okazaki, the Company's President and Chief Operating Officer, would succeed Dr. McHutchison as Chief Executive Officer, effective January 1, 2023
Departed

John G. McHutchison

Chief Executive Officer
ASMB · ASSEMBLY BIOSCIENCES, INC.
Effective
2022-12-31
Successor
Jason A. Okazaki
Filed
December 12, 2022, 6:59 PM ET
John G. McHutchison, A.O., M.D. would retire from his role as Chief Executive Officer effective December 31, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason A. Okazaki was appointed as Chief Executive Officer at ASSEMBLY BIOSCIENCES, INC..

Action
succeed
Role
Chief Executive Officer
Exact text from the filing
Jason A. Okazaki, the Company's President and Chief Operating Officer, would succeed Dr. McHutchison as Chief Executive Officer, effective January 1, 2023
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John G. McHutchison departed as Chief Executive Officer at ASSEMBLY BIOSCIENCES, INC..

Action
retire
Role
Chief Executive Officer
Exact text from the filing
John G. McHutchison, A.O., M.D. would retire from his role as Chief Executive Officer effective December 31, 2022
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ASSEMBLY BIOSCIENCES, INC.: Amended and restated Bylaws reducing stockholder meeting quorum from majority to one-third, deleting list of stockholders requirement, and updating advance notice provisions for universal proxy rules (effective 2022-12-07).

Change
bylaw amendment
Effective
2022-12-07
Exact text from the filing
On December 7, 2022, the Board approved an amendment and restatement of the Company's Amended and Restated Bylaws (the "Amended and Restated Bylaws").
View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR
accession 0000950170-22-026384
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.